ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Moderna has signed a new agreement with the Swiss drug services firm Lonza, which will establish a production line at its facility in Geleen, the Netherlands, to make the active ingredient for 300 million doses per year of Moderna’s COVID-19 variant vaccine candidate, which is pending regulatory approval. The plant could be running by the end of the year. Lonza agreed in May 2020 to produce Moderna’s original vaccine in Visp, Switzerland, and Portsmouth, New Hampshire. Moderna separately picked Thermo Fisher Scientific to fill and finish its COVID-19 vaccine in Greenville, North Carolina, starting later this year.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter